Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived XenograftsShunqiang Li, Ana M. González-Angulo, Dong Shen et al.|Cell Reports|2013Cited by 630
<i>PIK3CA</i> and <i>PIK3CB</i> Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor–Positive Breast CancerRobert J. Crowder, Matthew J. Ellis, Chanpheng Phommaly et al.|Cancer Research|2009Cited by 228
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancerCésar Sánchez, Matthew J. Ellis, X. Cynthia et al.|Breast Cancer Research|2011Cited by 185
Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast CancerJonathan T. Lei, Matthew J. Ellis, Raquel Mary Rodrigues Peres et al.|Cell Reports|2018Cited by 110
PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor-Positive Breast CancerChanpheng Phommaly, Matthew J. Ellis, Robert J. Crowder et al.|UNC Libraries|2020Cited by 11